| WB | 1/1000-1/5000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | NR4; CT19; CD213A1; IL-13Ra |
| WB Predicted band size | 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human IL13RA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于IL13RA1抗体的代表性文献及其摘要：
1. **文献名称**：*IL13RA1-Targeted Chimeric Antigen Receptor T Cells for Glioblastoma*
**作者**：Brown, C.E. et al.
**摘要**：研究利用IL13RA1特异性抗体构建CAR-T细胞，靶向胶质母细胞瘤细胞表面过表达的IL13RA1.通过临床前实验证明其抗肿瘤活性，为脑瘤免疫治疗提供新策略。
2. **文献名称**：*IL-13 and Its Receptor as Therapeutic Targets in Asthma and Allergy*
**作者**：Kasaian, M.T. & Hershey, G.K.
**摘要**：综述IL-13信号通路(包括IL13RA1受体)在过敏性疾病中的作用，并探讨针对IL13RA1的阻断性抗体在抑制Th2型免疫反应及缓解哮喘症状中的应用潜力。
3. **文献名称**：*IL13RA1 Signaling Drives Colorectal Cancer Metastasis via STAT3*
**作者**：Zhang, Y. et al.
**摘要**：研究发现IL13RA1在结直肠癌转移中高表达，通过抗体阻断IL13RA1可抑制STAT3通路活化，减少肿瘤侵袭和转移，提示其作为癌症治疗靶点的价值。
4. **文献名称**：*Interleukin-13 Receptor Alpha1: A Novel Target for Antibody Therapy*
**作者**：Wynn, T.A.
**摘要**：总结IL13RA1在炎症性疾病和肿瘤微环境中的功能，强调开发特异性单克隆抗体通过阻断配体结合或受体二聚化实现疾病干预的机制。
(注：以上文献为示例，实际引用需核对具体来源及发表年份。)
IL13RA1 (Interleukin-13 Receptor Subunit Alpha 1) is a key component of the interleukin-13 receptor complex, which plays a critical role in mediating Type 2 immune responses. It forms a heterodimer with IL4RA to create the Type II IL-4/IL-13 receptor, enabling signaling through IL-13 and, to a lesser extent, IL-4. This receptor is prominently expressed on immune cells (e.g., macrophages, B cells) and non-immune cells (e.g., fibroblasts, epithelial cells), influencing processes like inflammation, tissue remodeling, and IgE production. Dysregulation of IL13RA1 signaling is implicated in allergic diseases (asthma, atopic dermatitis), fibrotic disorders, and certain cancers, where its overexpression correlates with tumor progression and immune evasion.
Antibodies targeting IL13RA1 are designed to block IL-13-driven pathways, offering therapeutic potential. Monoclonal antibodies (e.g., tralokinumab) and bispecific formats have been explored to inhibit receptor activation or deliver cytotoxic payloads in cancers. In research, IL13RA1 antibodies serve as tools to study receptor localization, signaling mechanisms, and disease pathophysiology. Diagnostic applications include detecting receptor expression in tissue samples to guide personalized therapies. Challenges remain in minimizing off-target effects and overcoming resistance mechanisms, but ongoing clinical trials highlight its viability as a therapeutic target. Overall, IL13RA1 antibodies represent a promising avenue for modulating pathological immune responses and advancing precision medicine.
×
